RAReed Arneson

Reed Arneson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Reed Arneson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long Oligos: Direct Chemical Synthesis of Genes with up to 1,728 Nucleotides

    by Yipeng Yin, Reed Arneson, Yinan Yuan, Shiyue Fang

    The longest oligos that can be chemically synthesized using known methods are typically considered to be 200-mers. Here, we report direct synthesis of an 800-mer green fluorescent protein (GFP) gene and a 1,728-mer Φ29 DNA polymerase gene on an automated synthesizer. Key innovations that enabled the breakthrough include conducting the synthesis on the smooth surface of glass wool or glass bead rather than within the pores of traditional solid supports, and the use of the powerful catching-by-polymerization (CBP) method for the isolation of the full-length oligos from the crude mixture. Conducting the synthesis on smooth surface not only eliminated the steric hindrance that would otherwise prevent long oligo assembly, but also, surprisingly, drastically reduced the errors that commonly occur in traditional oligo synthesis. The long oligos were characterized by cloning followed by Sanger sequencing. We anticipate that the new method for long oligo synthesis will have a significant impact on projects in areas such as synthetic biology, gene editing, protein engineering, and many others.


  • Open Access

    The Naturally Occurring m1A RNA Modification Can Be Efficiently Incorporated into RNA by SARS-CoV-2 RdRp

    by Alexander Apostle, Reed Arneson, Yinan Yuan, Shiyue Fang

    When it is in the template RNA, the naturally occurring m1A epitranscriptomic RNA modification was recently reported to be able to stop the RNA polymerization reaction catalyzed by the RNA dependent RNA polymerase (RdRp) of SARS-CoV-2. In this report, we report that m1A via its triphosphate form (m1ATP) can be incorporated into RNA by the same RdRp. These two findings point a new direction for antiviral drug development based on m1A for combatting COVID-19. More broadly, it is possible that the large pool of epigenetic RNA as well as DNA modifications could serve as a treasury for drug discovery aimed at combating various infectious and other diseases.

  • Open Access

    Long Oligodeoxynucleotides: Chemical Synthesis, Isolation via Catching by Polymerization, Verification via Sequencing, and Gene Synthesis and Expression Demonstration

    by Yipeng Yin, Reed Arneson, Alexander Apostle, Adikari Eriyagama, Komal Chillar, Emma Burke, Martina Jahfetson, Yinan Yuan, Shiyue Fang

    Long oligodeoxynucleotides (ODNs) are segments of DNAs having over one hundred nucleotides (nt). They are typically assembled using enzymatic methods such as PCR and ligation from shorter 20 to 60 nt ODNs produced by automated de novo chemical synthesis. While these methods have made many projects in areas such as synthetic biology and protein engineering possible, they have various drawbacks. For example, they cannot produce genes and genomes with long repeats and have difficulty to produce sequences containing stable secondary structures. Here we report direct de novo chemical synthesis of 400 nt ODNs, and their isolation from complex reaction mixture using the catching-by-polymerization (CBP) method. To determine the authenticity of the ODNs, 399 and 401 nt ODNs were synthesized and purified with CBP. The two were joined together using Gibson assembly to give the 800 nt green fluorescent protein (GFP) gene construct. The sequence of the construct was verified via Sanger sequencing. To demonstrate the potential use of the long ODN synthesis method, the GFP gene was expressed in E. coli. The long ODN synthesis and isolation method presented here provides a pathway to the production of genes and genomes containing long repeats or stable secondary structures that cannot be produced or are highly challenging to produce using existing technologies.


  • Open Access

    Effects of Epitranscriptomic RNA Modifications on the Catalytic Activity of SARS-CoV-2 Replication Complex

    by Alexander Apostle, Yipeng Yin, Komal Chillar, Adikari M. D. N. Eriyagama, Reed Arneson, Emma Burke, Shiyue Fang, Yinan Yuan

    Like other viruses, SARS-CoV-2 causes different symptoms and different degrees of harmfulness to different individuals. Potential reasons include an individual’s viral dose exposure, the affinity of an individual’s ACE2 to the spike protein of the virus, and the ability of the individual’s induced immune system to neutralize the virus. Beyond these, an individual’s epitranscriptomic system could be among the causes as well. The viral RNA genome, once inside the host cell, can be subject to modifications by the host’s epitranscriptomic machinery. Because the machinery is different in different individuals, it is reasonable to believe that RNA modifications are different among different individuals, and can positively or negatively affect downstream events that involve the RNA such as replication of viral genome, generation of viral mRNAs, viral protein production, RNA recognition by host’s immune system, and packaging of RNA genome into new viral particles. In this context, we studied the effects of several RNA modifications including pseudouridine (Ψ), 5-methylcytosine (m5C), N6-methyladenosine (m6A), N1-methyladenosine (m1A) and N3-methylcytosine (m3C) on the catalytic activity of SARS-CoV-2 replication complex (SC2RC), which included RNA dependent RNA polymerase (RdRp). We found that Ψ, m5C, m6A and m3C had little effects on the activity, while m1A severely inhibited the enzyme. Both m1A and m3C disrupt canonical base pairing. It is interesting one of them inhibits the enzyme while the other does not. The fact that m1A inhibits SC2RC may imply that the modification can be difficult to identify using any method even though it may exist and play a critical role. Putting aside other mechanisms by which the modifications cause individualized symptoms, the results indicated that individuals with a higher chance of m1A modification may stop viral replication and have less severe symptoms. However, this contradicts the observations that individuals with clinical conditions such as cancer, obesity and diabetes, who have upregulated m1A modifications, are more vulnerable to COVID-19. This contradiction may be explained by the importance of the dynamic nature of epitranscriptomic modifications for viral survival.